Improving a Pharmaceutical Water System based on a Risk Analysis Approach - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Improving a Pharmaceutical Water System based on a Risk Analysis Approach
In this study, fault tree analysis applied to a water pretreatment and purification installation exposed cause-and-effect complex interrelations in possible fault events.


Pharmaceutical Technology



Figure 5 (FIGURES ARE COURTESY OF THE AUTHORS)
At the softener's battery outlet, good water hardness levels were achieved (<5 ppm calcium carbonate). At the RO system, water product conductivity values were <1.7 μS/cm, (see Figure 5). In this case, ionic removal gained in effectiveness compared with daily operation before performing any changes.


Figure 6 (FIGURES ARE COURTESY OF THE AUTHORS)
TOC levels from pretreatment to the RO system were reduced compared with those from a previous study in which levels of approximately 2000 ppb of carbon were detected. This result indicated that replacing the carbon–SILEX mixed bed by the new free-chlorine removal system was beneficial. At the same time, organic matter removal at the RO system was effective, as shown in Figure 6, where TOC values in water product were below 300 ppb.


Figure 7 (FIGURES ARE COURTESY OF THE AUTHORS)
Free-chlorine in water was kept over 0.2 ppm, even though it is consumed as a consequence of oxidative action on organic and microbiological matter through different pretreatment stages (see Figure 7). Free-chlorine removal mainly based on sodium meta-bisulfite dosage showed an almost total effectiveness. Outlet free-chlorine values were nearly undetectable, therefore membranes' deterioration risk was reduced to a minimum.


Figure 8 (FIGURES ARE COURTESY OF THE AUTHORS)
As a result of ensuring adequate free-chlorine levels throughout pretreatment stages and reducing stagnant zones by replacing mixed beds, good bioburden and endotoxin content control was achieved, with very low values within prearranged limits (see Figure 8). This result also facilitates a more viable work of the RO system and reduces biofilm formation hazard on membranes.

As a result of WPP process qualification, the study demonstrated that changes made to the installation and its operation ensure better performance as well as a water product obtained with water for injection quality according to USP and highly purified water quality according to EP.

Conclusion

Applying a risk analysis approach on a WPP process disclosed installation design and operational insufficiencies. A model obtained from the fault tree analysis method became a useful qualitative tool, revealing cause-and-effect complex interrelations between various fault events likely to arise. A model obtained from the failure modes and effects analysis method consolidated information from fault tree analysis and facilitated the establishment of priorities quantitatively on actions to be taken to correct or mitigate those failure modes according to their criticality. Such actions were directed to keep good care of reverse osmosis membranes and a safer reverse osmosis purification process.

Performance qualification carried out during 15 days demonstrated that, after prescribed modifications on the installation and its operation were made, functioning was improved from a chemical and microbiological point of view throughout the process stages, thereby ensuring a water product of pharmaceutical quality. However, risk-threat levels to which the system is subjected do not make it fully reliable. Therefore, the authors recommend that the continued use of water product obtained from this process be limited to washing operations and other technological applications as required. Its direct use in parenteral formulation shall be analyzed cautiously and only in a force majeure case.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here